Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2)
combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the
following surgical treatment and a favorable overall survival rate for stages IB2 and IIA2
cervical squamous cell carcinoma (SCC).
Phase:
Phase 2
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborators:
Asian Gynecologic Oncology Group Taiwanese Gynecologic Oncology Group